(Q43000509)

English

Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.

scientific article published on 8 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C. (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

Waleed K Al-Hamoudi

11

object named as

Waleed Al-hamoudi

1 reference

Europe PubMed Central

12 November 2017

author name string

Abdallah M AlQaraawi

1

1 reference

Europe PubMed Central

12 November 2017

Faisal M Sanai

2

1 reference

Europe PubMed Central

12 November 2017

Hussa Al-Husseini

3

1 reference

Europe PubMed Central

12 November 2017

Ali Albenmousa

4

1 reference

Europe PubMed Central

12 November 2017

Abdulmalik AlSheikh

5

1 reference

Europe PubMed Central

12 November 2017

Lubna Rizwan Ahmed

6

1 reference

Europe PubMed Central

12 November 2017

Ahmad Hersi

7

1 reference

Europe PubMed Central

12 November 2017

Molfi M Al-Otaibi

8

1 reference

Europe PubMed Central

12 November 2017

Mohammed Syed

9

1 reference

Europe PubMed Central

12 November 2017

Safiyya M Ali

10

1 reference

Europe PubMed Central

12 November 2017

Khalid A Alswat

12

1 reference

Europe PubMed Central

12 November 2017

Ayman A Abdo

13

1 reference

Europe PubMed Central

12 November 2017

publication date

8 October 2010

1 reference

Europe PubMed Central

12 November 2017

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

12 November 2017

56

1 reference

Europe PubMed Central

12 November 2017

4

1 reference

Europe PubMed Central

12 November 2017

1222-1228

1 reference

Europe PubMed Central

12 November 2017

https://scigraph.springernature.com/pub.10.1007/s10620-010-1417-9

0 references

Epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Mechanisms and significance of liver steatosis in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Hepatitis C virus and glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1417-9

21 January 2018

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis C virus genotypes in Saudi Arabia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10620-010-1417-9

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43000509&oldid=1946022659"